Insurance Denials, Delays Limit Pediatric Asthma Biologics
Approximately 40% of insurance requests for pediatric asthma biologic therapies are denied, with approvals taking more than a month on average.
Tag: reslizumab Cinqair
Insurance Denials, Delays Limit Pediatric Asthma Biologics
Approximately 40% of insurance requests for pediatric asthma biologic therapies are denied, with approvals taking more than a month on average.
Read More
COPD, Asthma, and Pharmacology
Several new pharmacological treatments for COPD and asthma have appeared on the respiratory market in the past year but what are the advantages these new generation pharmaceuticals?
Read More
FDA Panel Backs Reslizumab for Adults With Severe Asthma
Reslizumab has been recommended for approval by an FDA advisory committee for use in treating adults 18 years and older with asthma.
Read More